Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kamada ( (IL:KMDA) ) has shared an announcement.
Kamada Ltd. announced it will hold its Annual General Meeting of Shareholders on December 10, 2025, in Rehovot, Israel. The meeting will address several key proposals, including the re-election of board members, approval of options for the CEO, amendments to the compensation policy, and changes to the Articles of Association to enhance indemnification and insurance for directors and officers. Additionally, the re-appointment of Kost Forer Gabbay & Kasierer as independent auditors will be ratified. These decisions are crucial for maintaining corporate governance and ensuring compliance with Israeli laws, potentially impacting shareholder value and the company’s operational framework.
The most recent analyst rating on (IL:KMDA) stock is a Buy with a ILs11.00 price target. To see the full list of analyst forecasts on Kamada stock, see the IL:KMDA Stock Forecast page.
More about Kamada
Kamada Ltd. operates in the biopharmaceutical industry, focusing on the development, production, and marketing of specialty plasma-derived protein therapeutics. The company is based in Rehovot, Israel, and is known for its innovative treatments for rare and serious conditions.
Average Trading Volume: 48,118
Technical Sentiment Signal: Buy
Current Market Cap: ILs1.32B
For detailed information about KMDA stock, go to TipRanks’ Stock Analysis page.